

**NUDERMRXPAK 60- calcipotriene, dimethicone**  
**NuCare Pharmaceuticals, Inc.**

-----  
**FOR TOPICAL DERMATOLOGIC USE ONLY.**


**Rx only**

**Not for Ophthalmic, Oral or Intravaginal Use.**

**DESCRIPTION**

Calcipotriene Cream, 0.005% contains calcipotriene monohydrate, a synthetic vitamin D<sub>3</sub> derivative, for topical dermatological use.

Chemically, calcipotriene monohydrate is (5Z,7E,22E,24S)-24-cyclopropyl-9,10-secochole-5,7,10(19),22-tetraene-1 $\alpha$ ,3 $\beta$ ,24-triol monohydrate, with the empirical formula C<sub>27</sub>H<sub>40</sub>O<sub>3</sub>•H<sub>2</sub>O, a molecular weight of 430.6, and the following structural formula:



Calcipotriene monohydrate is a white or off-white crystalline substance. Calcipotriene Cream contains calcipotriene monohydrate equivalent to 50  $\mu$ g/g anhydrous calcipotriene in a cream base of ceteryl alcohol, ceteth-20, diazolidinyl urea, dichlorobenzyl alcohol, dibasic sodium phosphate, edetate disodium, dl-alpha tocopherol, glycerin, mineral oil, petrolatum, and water.

**CLINICAL PHARMACOLOGY**

In humans, the natural supply of vitamin D depends mainly on exposure to the ultraviolet rays of the sun for conversion of 7-dehydrocholesterol to vitamin D<sub>3</sub> (cholecalciferol) in the skin. Calcipotriene is a synthetic analog of vitamin D<sub>3</sub>.

Clinical studies with radiolabelled calcipotriene ointment indicate that approximately 6% ( $\pm$  3%, SD) of the applied dose of calcipotriene is absorbed systemically when the ointment is applied topically to psoriasis plaques, or 5% ( $\pm$  2.6%, SD) when applied to normal skin, and much of the absorbed active is converted to inactive metabolites within 24 hours of application. Systemic absorption of the cream has not been studied.

Vitamin D and its metabolites are transported in the blood, bound to specific plasma proteins. The active form of the vitamin, 1,25-dihydroxy vitamin D<sub>3</sub> (calcitriol), is known to be recycled via the liver and excreted in the bile. Calcipotriene metabolism following

systemic uptake is rapid, and occurs via a similar pathway to the natural hormone.

## **CLINICAL STUDIES**

Adequate and well-controlled trials of patients treated with Calcipotriene Cream have demonstrated improvement usually beginning after 2 weeks of therapy. This improvement continued with approximately 50% of patients showing at least marked improvement in the signs and symptoms of psoriasis after 8 weeks of therapy, but only approximately 4% showed complete clearing.

## **INDICATIONS AND USAGE**

Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established.

## **CONTRAINDICATIONS**

Calcipotriene Cream is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation. It should not be used by patients with demonstrated hypercalcemia or evidence of vitamin D toxicity. Calcipotriene Cream should not be used on the face.

## **WARNINGS**

Contact dermatitis, including allergic contact dermatitis, has been observed with the use of Calcipotriene Cream.

## **PRECAUTIONS**

### **General**

Use of Calcipotriene Cream may cause transient irritation of both lesions and surrounding uninvolved skin. If irritation develops, Calcipotriene Cream should be discontinued.

For external use only. Keep out of the reach of children. Always wash hands thoroughly after use.

Reversible elevation of serum calcium has occurred with use of topical calcipotriene. If elevation in serum calcium outside the normal range should occur, discontinue treatment until normal calcium levels are restored.

### **Information for Patients**

Patients using Calcipotriene Cream should receive the following information and instructions:

1. This medication is to be used only as directed by the physician. It is for external use only. Avoid contact with the face or eyes. As with any topical medication, patients

- should wash their hands after application.
2. This medication should not be used for any disorder other than that for which it was prescribed.
  3. Patients should report to their physician any signs of adverse reactions.
  4. Patients that apply Calcipotriene Cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.).

### **Carcinogenesis, Mutagenesis, Impairment of Fertility**

When calcipotriene was applied topically to mice for up to 24 months at dosages of 3, 10 and 30  $\mu\text{g}/\text{kg}/\text{day}$  (corresponding to 9, 30 and 90  $\mu\text{g}/\text{m}^2/\text{day}$ ), no significant changes in tumor incidence were observed when compared to control. In a study in which albino hairless mice were exposed to both UVR and topically applied calcipotriene, a reduction in the time required for UVR to induce the formation of skin tumors was observed (statistically significant in males only), suggesting that calcipotriene may enhance the effect of UVR to induce skin tumors. Patients that apply Calcipotriene Cream to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.). Physicians may wish to limit or avoid use of phototherapy in patients that use Calcipotriene Cream.

Calcipotriene did not elicit any mutagenic effects in an Ames mutagenicity assay, a mouse lymphoma TK locus assay, a human lymphocyte chromosome aberration assay, or in a micronucleus assay conducted in mice.

Studies in rats at doses up to 54  $\mu\text{g}/\text{kg}/\text{day}$  (324  $\mu\text{g}/\text{m}^2/\text{day}$ ) of calcipotriene indicated no impairment of fertility or general reproductive performance.

### **Pregnancy**

#### *Teratogenic Effects*

Studies of teratogenicity were done by the oral route where bioavailability is expected to be approximately 40-60% of the administered dose. Increased rabbit maternal and fetal toxicity was noted at 12  $\mu\text{g}/\text{kg}/\text{day}$  (132  $\mu\text{g}/\text{m}^2/\text{day}$ ). Rabbits administered 36  $\mu\text{g}/\text{kg}/\text{day}$  (396  $\mu\text{g}/\text{m}^2/\text{day}$ ) resulted in fetuses with a significant increase in the incidences of pubic bones, forelimb phalanges, and incomplete bone ossification. In a rat study, oral doses of 54  $\mu\text{g}/\text{kg}/\text{day}$  (318  $\mu\text{g}/\text{m}^2/\text{day}$ ) resulted in a significantly higher incidence of skeletal abnormalities consisting primarily of enlarged fontanelles and extra ribs. The enlarged fontanelles are most likely due to calcipotriene's effect upon calcium metabolism. The maternal and fetal calculated no-effect exposures in the rat (43.2  $\mu\text{g}/\text{m}^2/\text{day}$ ) and rabbit (17.6  $\mu\text{g}/\text{m}^2/\text{day}$ ) studies are approximately equal to the expected human systemic exposure level (18.5  $\mu\text{g}/\text{m}^2/\text{day}$ ) from dermal application. There are no adequate and well-controlled studies in pregnant women. Therefore, Calcipotriene Cream should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### **Nursing Mothers**

There is evidence that maternal 1,25-dihydroxy vitamin D<sub>3</sub> (calcitriol) may enter the fetal circulation, but it is not known whether it is excreted in human milk. The systemic disposition of calcipotriene is expected to be similar to that of the naturally occurring vitamin. Because many drugs are excreted in human milk, caution should be exercised when Calcipotriene Cream is administered to a nursing woman.

## **Pediatric Use**

Safety and effectiveness of Calcipotriene Cream in pediatric patients have not been established. Because of a higher ratio of skin surface area to body mass, pediatric patients are at greater risk than adults of systemic adverse effects when they are treated with topical medication.

## **Geriatric Use**

Of the total number of patients in clinical studies of calcipotriene cream, approximately 15% were 65 or older, while approximately 3% were 75 and over. There were no significant differences in adverse events for subjects over 65 years compared to those under 65 years of age. However, the greater sensitivity of older individuals cannot be ruled out.

## **ADVERSE REACTIONS**

### **Clinical Trials Experience**

In controlled clinical trials, the most frequent adverse experiences reported for Calcipotriene Cream, 0.005% were cases of skin irritation, which occurred in approximately 10-15% of patients. Rash, pruritus, dermatitis and worsening of psoriasis were reported in 1 to 10% of patients.

### **Postmarketing Experience**

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

The following adverse reactions associated with the use of Calcipotriene Cream have been identified post-approval: contact dermatitis including allergic contact dermatitis.

## **OVERDOSAGE**

Topically applied calcipotriene can be absorbed in sufficient amounts to produce systemic effects. Elevated serum calcium has been observed with excessive use of topical calcipotriene. If elevation in serum calcium should occur, discontinue treatment until normal calcium levels are restored. (See PRECAUTIONS.)

## **DOSAGE AND ADMINISTRATION**

Apply a thin layer of Calcipotriene Cream to the affected skin twice daily and rub in gently and completely. The safety and efficacy of Calcipotriene Cream have been demonstrated in patients treated for eight weeks.

## **HOW SUPPLIED**

Calcipotriene Cream, 0.005% is available in:  
60 gram aluminum tubes (NDC 66993-877-61)

## **STORAGE**

Store at controlled room temperature 15°C - 25°C (59°F - 77°F). Do not freeze.



Manufactured for: **Prasco Laboratories**, Mason, OH 45040 USA

Manufactured by: LEO Laboratories Ltd., Dublin 12, Ireland

**To report SUSPECTED ADVERSE REACTIONS, contact LEO Pharma Inc. at 1-877-494-4536 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)**

Revised 06/2017

## **Dimethicone , 118mg**

Drug Facts

## **Active Ingredient**

Dimethicone 5.0%

## **Purpose**

Skin Protectant

## **Indications & Usage**

### **Uses**

For the treatment and / or prevention of diaper rash temporarily protects and helps relieve chapped or cracked skin.

## **Warnings**

### **For external use only.**

- When using this product
- do not get into eyes

### **Do not use on**

- deep or puncture wounds
- animal bites
- serious burns

## **Stop Use Section**

### **Stop Use and ask a doctor if**

condition worsens

symptoms last more than 7 days or clear up and occur again within a few days

## **Keep Out Of Reach Of Children**

If swallowed, get medical help or contact a Poison Control Center right away.

## **Dosage and Administration**

### **Directions**

- Cleanse skin with Thera Moisturizing Body Cleanser or Thera Foaming Body Cleanser
- Apply cream liberally until entire area is covered
- Apply as needed

## **Other Information**

Store at 40-95°F (4-35°C)

## **Inactive Ingredients**

Inactive Ingredients:

Purified Water, Glyceryl Stearate, PEG 100 Stearate, Stearic Acid, Aleurites Moluccana Seed Oil, Cetyl Alcohol, Glycerin, Butylene Glycol, Carthamus Tinctorius (Safflower) Seed Oil, Dimethicone Crosspolymer, Calcium Pantothenate (Vitamin B5), Maltodextrin, Niacinamide (Vitamin B3), Pyridoxine HCL (Vitamin B6), Silica, Sodium Ascorbyl Phosphate (Vitamin C), Sodium Starch Octenylsuccinate, Tocopheryl Acetate (Vitamin E), Disodium EDTA, Sodium Hyaluronate, Aloe Barbadensis Leaf Extract, Zingiber Officinale (Ginger) Root Extract, Carthamus Tinctorius (Safflower) Oleosomes, Fragrance, Phenoxyethanol, Caprylyl Glycol, Chlorphenesin, Bisabolol, Lysine, Histidine, Arginine, Aspartic Acid, Threonine, Serine, Glutamic Acid, Proline, Glycine, Alanine, Valine, Methionine, Isoleucine, Leucine, Tyrosine, Phenylalanine, Cysteine, Triethanolamine

## **Questions**

Questions ?

Call 1-800-777-4908

# CALCIPOTRIENE 60G

NDC 66993-877-61

PRASCO

Calcipotriene Cream, 0.005%

Net Wt. 60 g

Rx only



# DIMETHICONE 68599-0213-4

NDC 68599-0213-4

# Thera<sup>®</sup>

## DIMETHICONE BODY SHIELD



Provides mild skin protection  
against irritation from  
chapped or cracked skin.

Single Patient Use

### THERAPY

for your skin

**MCKESSON**

NET CONTENTS 4 fl oz (118 mL)  
MFR # 53-DS4



ROOM NO.

NAME

#### Drug Facts

Active ingredient	Purpose
Dimethicone 5%	Skin Protectant

**Uses** • for the treatment and/or prevention of diaper rash • temporarily protects and helps relieve chapped or cracked skin

#### Warnings

For external use only.

**When using this product** • do not get into eyes

**Skip use and ask a doctor if** • condition worsens • symptoms last more than 7 days or clear up and occur again within a few days

**Do not use on** • deep or puncture wounds • animal bites • serious burns

**Keep out of reach of children.** If swallowed, get medical help or contact a poison control center right away.

**Directions** • Cleanse skin with Thera Moisturizing Body Cleanser or Thera Foaming Body Cleanser • Apply cream liberally until entire area is covered • Apply as needed


#### Inactive ingredients

Purified Water, Glycerol Stearate, PEG 100 Stearate, Stearic Acid, Aleurites Moluccana Seed Oil, Cetyl Alcohol, Glycerin, Butylene Glycol, Carthamus Tinctorius (Safflower) Seed Oil, Dimethicone Crosspolymer, Calcium Pantothenate (Vitamin B5), Methylcellulose, Nicotinamide (Vitamin B3), Pyridoxine HCl (Vitamin B6), Silica, Sodium Ascorbyl Phosphate (Vitamin C), Sodium Starch Octenylsuccinate, Tocopherol Acetate (Vitamin E), Disodium EDTA, Sodium Hyaluronate, Aloe Barbadosis Leaf Extract, Zingiber Officinale (Ginger) Root Extract, Carthamus Tinctorius (Safflower) Oleosomes, Fragrance, Phenoxyethanol, Caprylyl Glycol, Chlorphenesin, Bisabolol, Lysine, Histidine, Arginine, Aspartic Acid, Threonine, Serine, Glutamic Acid, Proline, Glycine, Alanine, Valine, Methionine, Isoleucine, Leucine, Tyrosine, Phenylalanine, Cysteine, Threonolactone.

Thera<sup>®</sup> is a specially formulated skin care line that helps restore skin to a healthy condition.  
Store at 48-55°F (4-32°C).  
Questions? Call 1-866-777-4968.  
Distributed by McKesson Medical-Surgical Inc.,  
Richmond, VA 23233 PPN 88819 Made in USA

## NuDermRXPak 60





## NUDERMRXPAK 60

calcipotriene, dimethicone kit

### Product Information

<b>Product Type</b>	HUMAN PRESCRIPTION DRUG	<b>Item Code (Source)</b>	NDC:70859-055
---------------------	-------------------------	---------------------------	---------------

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:70859-055-01	1 in 1 KIT	06/16/2020	

### Quantity of Parts

Part #	Package Quantity	Total Product Quantity
Part 1	1 TUBE	60 g
Part 2	1 BOTTLE	118 mg

## Part 1 of 2

## CALCIPOTRIENE

calcipotriene cream

### Product Information

**Item Code (Source)** NDC:66993-877

**Route of Administration** TOPICAL

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>CALCIPOTRIENE</b> (UNII: 143NQ3779B) (CALCIPOTRIENE - UNII:143NQ3779B)	CALCIPOTRIENE	50 ug in 1 g

### Inactive Ingredients

Ingredient Name	Strength
<b>GLYCERIN</b> (UNII: PDC6A3C00X)	
<b>PETROLATUM</b> (UNII: 4T6H12BN9U)	
<b>WATER</b> (UNII: 059QF0KO0R)	
<b>.ALPHA.-TOCOPHEROL, DL-</b> (UNII: 7QWA1RIO01)	
<b>EDETATE DISODIUM</b> (UNII: 7FLD91C86K)	
<b>MINERAL OIL</b> (UNII: T5L8T28FGP)	
<b>CETOSTEARYL ALCOHOL</b> (UNII: 2DMT128M1S)	
<b>CETETH-20</b> (UNII: I835H2IHHX)	
<b>DICHLOROBENZYL ALCOHOL</b> (UNII: 1NKX3648J9)	
<b>SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM</b> (UNII: GR686LBA74)	
<b>DIAZOLIDINYL UREA</b> (UNII: H5RIZ3MPW4)	

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:66993-877-61	1 in 1 CARTON		
1		60 g in 1 TUBE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA authorized generic	NDA020554	10/01/1996	

Part 2 of 2

**DIMETHICONE**

body shield cream

### Product Information

**Item Code (Source)** NDC:68599-0213

**Route of Administration** TOPICAL

### Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
<b>DIMETHICONE</b> (UNII: 92RU3N3Y1O) (DIMETHICONE - UNII:92RU3N3Y1O)	DIMETHICONE	50 ug in 1 mg

### Inactive Ingredients

Ingredient Name	Strength
<b>STEARIC ACID</b> (UNII: 4ELV7Z65AP)	
<b>LEVOMENOL</b> (UNII: 24WE03BX2T)	
<b>MALTODEXTRIN</b> (UNII: 7CVR7L4A2D)	
<b>LYSINE</b> (UNII: K3Z4F929H6)	
<b>SODIUM ASCORBYL PHOSPHATE</b> (UNII: 836SJG51DR)	
<b>TROLAMINE</b> (UNII: 9O3K93S3TK)	
<b>NIACINAMIDE</b> (UNII: 25X5118RD4)	
<b>EDETATE DISODIUM ANHYDROUS</b> (UNII: 8NLQ36F6MM)	
<b>SILICON DIOXIDE</b> (UNII: ETJ7Z6XBU4)	
<b>PYRIDOXINE HYDROCHLORIDE</b> (UNII: 68Y4CF58BV)	
<b>CHLORPHENESIN</b> (UNII: I670DAL4SZ)	
<b>ALANINE</b> (UNII: OF5P57N2ZX)	
<b>GLYCERIN</b> (UNII: PDC6A3C0OX)	
<b>GINGER</b> (UNII: C5529G5JPQ)	
<b>VALINE</b> (UNII: HG18B9YRS7)	
<b>HISTIDINE</b> (UNII: 4QD397987E)	
<b>GLYCINE</b> (UNII: TE7660XO1C)	
<b>PEG-100 STEARATE</b> (UNII: YD01N1999R)	
<b>.ALPHA.-TOCOPHEROL ACETATE</b> (UNII: 9E8X80D2L0)	
<b>CETYL ALCOHOL</b> (UNII: 936JST6JCN)	
<b>PHENOXYETHANOL</b> (UNII: HIE492ZZ3T)	
<b>OCTENYLSUCCINIC ACID</b> (UNII: 12UZE4X73L)	
<b>THREONINE</b> (UNII: 2ZD004190S)	
<b>CAPRYLYL GLYCOL</b> (UNII: 00YIU5438U)	
<b>GLUTAMIC ACID</b> (UNII: 3KX376GY7L)	
<b>ISOLEUCINE</b> (UNII: 04Y7590D77)	
<b>PHENYLALANINE</b> (UNII: 47E5O17Y3R)	
<b>CALCIUM PANTOTHENATE</b> (UNII: 568ET80C3D)	
<b>HYALURONATE SODIUM</b> (UNII: YSE9PPT4TH)	
<b>BUTYLENE GLYCOL</b> (UNII: 3XUS85K0RA)	
<b>PROLINE</b> (UNII: 9DLQ4CIU6V)	
<b>CYSTEINE</b> (UNII: K848JZ4886)	
<b>METHIONINE</b> (UNII: AE28F7PNPL)	

<b>KUKUI NUT OIL</b> (UNII: TP11QR7B8R)
<b>ARGININE</b> (UNII: 94ZLA3W45F)
<b>TYROSINE</b> (UNII: 42HK56048U)
<b>ALOE VERA LEAF</b> (UNII: ZY81Z83H0X)
<b>SAFFLOWER OIL</b> (UNII: 65UEH262IS)
<b>GLYCERYL MONOSTEARATE</b> (UNII: 230OU9XXE4)
<b>DIMETHICONE CROSSPOLYMER (450000 MPA.S AT 12% IN CYCLOPENTASILOXANE)</b> (UNII: UF7620L1W6)
<b>SERINE</b> (UNII: 452VLY9402)
<b>ASPARTIC ACID</b> (UNII: 30KYC7MIAI)
<b>WATER</b> (UNII: 059QF0KO0R)
<b>CARTHAMUS TINCTORIUS (SAFFLOWER) OLEOSOMES</b> (UNII: 9S60Q72309)
<b>LEUCINE</b> (UNII: GMW67QNF9C)

### Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:68599-0213-4	118 mg in 1 BOTTLE; Type 0: Not a Combination Product		

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
OTC monograph final	part347	08/12/2019	

### Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA authorized generic	NDA020554	10/01/1996	

**Labeler** - NuCare Pharmaceuticals,Inc. (010632300)

### Establishment

Name	Address	ID/FEI	Business Operations
NuCare Pharmaceuticals, Inc.		010632300	manufacture(70859-055)

Revised: 5/2021

NuCare Pharmaceuticals, Inc.